AstraZeneca Plc (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the Committee for Medicinal Products for..

AstraZeneca PLC (LON:AZN), today announced Q1 2019 results. Results in the first quarter were supported by Product Sales growth of 10% (14% at CER1) to $5,465m, a reflection of the..

AstraZeneca Plc (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced the European Commission has approved Lynparza (olaparib)..

AstraZeneca Plc (LON:AZN) and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration..

AstraZeneca Plc (LON:AZN) has entered into a global development and commercialisation collaboration agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for trastuzumab deruxtecan (DS-8201), a proprietary antibody-drug conjugate (ADC) and..

AstraZeneca PLC (LON:AZN), today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1..

AstraZeneca Plc (LON:AZN), today announced that The European Commission (EC) has approved Forxiga (dapagliflozin) for use in type-1 diabetes (T1D) as an adjunct to insulin in patients with a BMI..

AstraZeneca Plc (LON:AZN), The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for saracatinib, a potential new medicine for the treatment of idiopathic pulmonary fibrosis (IPF),..

AstraZeneca Plc (LON:AZN) and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the Committee for Medicinal Products for..

AstraZeneca Plc (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced positive results from the Phase III POLO..

AstraZeneca PLC (LON:AZN), The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of..

AstraZeneca PLC (LON:AZN), today announced full year results for the Q4 2018. The final quarter of the year saw a very strong performance, including Product Sales growth of 5% (8%..

AstraZeneca Plc (LON:AZN) and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for MEDI8897,..

AstraZeneca Plc (LON:AZN) and its global biologics research and development arm, MedImmune, has completed the agreement to sell its US rights to Synagis (palivizumab), used for the prevention of serious..

AstraZeneca Plc (LON:AZN) today announced that the Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoints for the treatment of patients with anaemia in chronic..

AstraZeneca Plc (LON:AZN) today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has now received formal marketing authorisation from the National Medical Products Administration (NMPA)..

AstraZeneca PLC (LON:AZN) today announced the following changes in respect of Non-Executive Directors. New Non-Executive Director With effect from 1 January 2019, Professor Tony Mok is appointed as a Non-Executive..

AstraZeneca Plc (LON:AZN) announced the completion of agreement to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan)..

AstraZeneca Plc (LON:AZN) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Fasenra (benralizumab) for the treatment of Eosinophilic Granulomatosis with Polyangiitis..

AstraZeneca Plc (LON:AZN) and MedImmune, its global biologics research and development arm, announced today final overall survival (OS) results for the Phase III MYSTIC trial, a randomised, open-label, multi-centre, global..